How to buy BridgeBio Pharma stock | $56.86

BridgeBio Pharma, Inc is a biotechnology business based in the US. BridgeBio Pharma shares (BBIO) are listed on the NASDAQ and all prices are listed in US Dollars. BridgeBio Pharma employs 369 staff and has a trailing 12-month revenue of around USD$21.9 million.

How to buy shares in BridgeBio Pharma

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for BridgeBio Pharma. Find the stock by name or ticker symbol: BBIO. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until BridgeBio Pharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$56.86, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of BridgeBio Pharma, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of BridgeBio Pharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

BridgeBio Pharma share price

Use our graph to track the performance of BBIO stocks over time.

BridgeBio Pharma shares at a glance

• Key figures

Information last updated 2020-12-27.

Latest market close	USD$56.86
52-week range	USD$14.23 - USD$70.56
50-day moving average	USD$52.7921
200-day moving average	USD$38.1195
Wall St. target price	USD$56.11
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-10.901

Buy BridgeBio Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy BridgeBio Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of BridgeBio Pharma, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BridgeBio Pharma price performance over time

Historical closes compared with the close of $56.86 from 2020-12-09

1 week (2021-01-15)	-17.13%
1 month (2020-12-22)	-16.27%
3 months (2020-10-22)	41.41%
6 months (2020-07-22)	84.10%

1 year (2020-01-22)	66.45%
2 years (2019-01-18)	N/A
3 years (2018-01-18)	N/A
5 years (2016-01-18)	N/A

BridgeBio Pharma financials

Revenue TTM	USD$21.9 million
Gross profit TTM	USD$38.1 million
Return on assets TTM	-37.25%
Return on equity TTM	-122.43%
Profit margin	0%
Book value	$3.918
Market capitalisation	USD$8.5 billion

TTM: trailing 12 months

Shorting BridgeBio Pharma shares

There are currently 11.0 million BridgeBio Pharma shares held short by investors – that's known as BridgeBio Pharma's "short interest". This figure is 0% up from 11.0 million last month.

There are a few different ways that this level of interest in shorting BridgeBio Pharma shares can be evaluated.

BridgeBio Pharma's "short interest ratio" (SIR)

BridgeBio Pharma's "short interest ratio" (SIR) is the quantity of BridgeBio Pharma shares currently shorted divided by the average quantity of BridgeBio Pharma shares traded daily (recently around 654689.50506857). BridgeBio Pharma's SIR currently stands at 16.77. In other words for every 100,000 BridgeBio Pharma shares traded daily on the market, roughly 16770 shares are currently held short.

However BridgeBio Pharma's short interest can also be evaluated against the total number of BridgeBio Pharma shares, or, against the total number of tradable BridgeBio Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BridgeBio Pharma's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 BridgeBio Pharma shares in existence, roughly 90 shares are currently held short) or 0.2141% of the tradable shares (for every 100,000 tradable BridgeBio Pharma shares, roughly 214 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against BridgeBio Pharma.

Find out more about how you can short BridgeBio Pharma stock.

BridgeBio Pharma share dividends

We're not expecting BridgeBio Pharma to pay a dividend over the next 12 months.

BridgeBio Pharma overview

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 20 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, an oral small molecule transthyretin (TTR), which is ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license agreements with the Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc.; strategic collaboration agreements with Johns Hopkins University and University of Florida; collaboration with University of Colorado Anschutz Medical Campus to advance novel research on genetically driven diseases into therapeutic applications for patients; collaboration with Salk Institute for Biological Studies; and Maze Therapeutics establishes a joint venture, Contour Therapeutics to advance precision medicine to treat cardiovascular diseases. The company was founded in 2015 and is headquartered in Palo Alto, California.

Frequently asked questions

• What percentage of BridgeBio Pharma is owned by insiders or institutions?

  Currently 8.89% of BridgeBio Pharma shares are held by insiders and 101.869% by institutions.

• How many people work for BridgeBio Pharma?

  Latest data suggests 369 work at BridgeBio Pharma.

• When does the fiscal year end for BridgeBio Pharma?

  BridgeBio Pharma's fiscal year ends in December.

• Where is BridgeBio Pharma based?

  BridgeBio Pharma's address is: 421 Kipling Street, Palo Alto, CA, United States, 94301

• What is BridgeBio Pharma's ISIN number?

  BridgeBio Pharma's international securities identification number is: US10806X1028

• What is BridgeBio Pharma's CUSIP number?

  BridgeBio Pharma's Committee on Uniform Securities Identification Procedures number is: 10806X102